Ameriprise
PTGX icon

Ameriprise’s Protagonist Therapeutics PTGX Stock Holding History

Ameriprise’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.6M Sell
143,810
-1,880
-1% -$196K ﹤0.01% 1635
2026
Q1 		$15.4M Sell
145,690
-23,828
-14% -$2.11M ﹤0.01% 1593
2025
Q4 		$14.8M Buy
169,518
+16,327
+11% +$1.34M ﹤0.01% 1634
2025
Q3 		$10.2M Sell
153,191
-15,180
-9% -$863K ﹤0.01% 1895
2025
Q2 		$9.31M Buy
168,371
+31,529
+23% +$1.51M ﹤0.01% 1872
2025
Q1 		$6.62M Sell
136,842
-4,545
-3% -$190K ﹤0.01% 2094
2024
Q4 		$5.46M Sell
141,387
-2,420
-2% -$106K ﹤0.01% 2296
2024
Q3 		$6.47M Buy
+143,807
New +$5.81M ﹤0.01% 2190
2023
Q3 		– Sell
-99,930
Closed -$2.76M – 3951
2023
Q2 		$2.76M Buy
99,930
+81,572
+444% +$2.04M ﹤0.01% 2714
2023
Q1 		$422K Buy
+18,358
New +$308K ﹤0.01% 3491
2021
Q2 		– Sell
-28,488
Closed -$737K – 3953
2021
Q1 		$737K Sell
28,488
-38,367
-57% -$971K ﹤0.01% 3258
2020
Q4 		$1.35M Buy
+66,855
New +$1.44M ﹤0.01% 2953

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Ameriprise's PTGX Position: Q2 2026 in Review

Ameriprise reduced its Protagonist Therapeutics (PTGX) stake by 1.3% in Q2 2026, selling an estimated $196K and leaving 143,810 shares worth $17.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1635.

Ameriprise first reported a position in PTGX in Q4 2020 and has held it in 12 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Ameriprise held 143,810 shares of Protagonist Therapeutics worth $17.6M as of Q2 2026.
  • Ameriprise sold 1,880 Protagonist Therapeutics shares in Q2 2026, an estimated $196K.
  • Protagonist Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #1635 holding.
  • Ameriprise first reported a position in Protagonist Therapeutics in Q4 2020 and has held it in 12 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.